Literature DB >> 1734909

P-31 magnetic resonance spectroscopy in polymyositis and dermatomyositis. Altered energy utilization during exercise.

E D Newman1, R J Kurland.   

Abstract

OBJECTIVE: To explore alterations in energy utilization as a potential etiology for weakness in polymyositis and dermatomyositis (PM/DM).
METHODS: P-31 magnetic resonance spectroscopy studies were performed in patients with acute and treated PM/DM and in normal controls, at rest and with exercise.
RESULTS: Patients with acute and treated PM/DM showed increased ratios of inorganic phosphate to phosphocreatine (PCr) during exercise, with loss of ATP disproportional to loss of PCr.
CONCLUSION: This study demonstrates changes in energy utilization in PM/DM, thus supporting the notion of a metabolic etiology for the weakness associated with these diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1734909     DOI: 10.1002/art.1780350212

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  4 in total

Review 1.  Laboratory evaluation of the inflammatory myopathies.

Authors:  L G Rider; F W Miller
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

Review 2.  Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies.

Authors:  J H Park; N J Olsen
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.686

3.  Voluntary activation failure is detectable in some myositis patients with persisting quadriceps femoris weakness: an observational study.

Authors:  Catherine B Molloy; Ahmed O Al-Omar; Kathryn T Edge; Robert G Cooper
Journal:  Arthritis Res Ther       Date:  2006-04-10       Impact factor: 5.156

4.  Idiopathic inflammatory myopathy human derived cells retain their ability to increase mitochondrial function.

Authors:  Carla Basualto-Alarcón; Félix A Urra; María Francisca Bozán; Fabián Jaña; Alejandra Trangulao; Jorge A Bevilacqua; J César Cárdenas
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.